Sacubitril/Valsartan Comparable to Enalapril in Pediatric Heart Failure, unravels study
Researchers have discovered that sacubitril/valsartan, the angiotensin receptor-neprilysin inhibitor (ARNI), is equivalent to the conventional angiotensin-converting enzyme (ACE) inhibitor enalapril in treating heart failure (HF) with systemic left ventricular systolic dysfunction (LVSD) in children. A recent study was conducted by Robert S. and colleagues which was published in the journal Circulation.
The primary objective of the PANORAMA-HF trial was to compare sacubitril/valsartan with enalapril in pediatric HF patients and check whether sacubitril/valsartan was superior to enalapril. The clinical outcomes evaluated were NYHA/Ross classification, patient quality of life, and biomarkers such as NT-proBNP over 52 weeks.
This randomized, double-blind study enrolled 375 children (mean age 8.1±5.6 years, 52% female) with HF due to systemic LVSD. Participants were assigned to either sacubitril/valsartan (N=187) or enalapril (N=188). The first major global rank endpoint evaluated the patients in relation to clinical events, which are mortality, urgent heart transplant listing, requirement of mechanical life support, worsening HF, NYHA/Ross class, Patient Global Impression of Severity (PGIS), and Pediatric Quality of Life Inventory. Secondary outcomes involved changes in NT-proBNP levels and safety assessments at 52 weeks.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.